Saturday 17 October 2026
Export MLYS’s income statement to Excel — free account
Mineralys Therapeutics, Inc.
MLYS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 331.8% and free cash flow fell 7.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
20.30
1.34
−6.19%
Follow MLYS
Mineralys Therapeutics, Inc. (MLYS) P/E ratio
Mineralys Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MRVI Maravai LifeSciences Holdings, Inc. compare | n/m |
| PVLA Palvella Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| MLYS Mineralys Therapeutics, Inc. | n/m |
| URGN Urogen Pharma compare | n/m |
| ZYME Zymeworks Inc. compare | n/m |
| AGIO Agios Pharmaceuticals, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)